Criteria for drug administration for filariasis set
by T. Villavert
Iloilo City (10 October) -- The Iloilo Provincial Health Office (PHO-Iloilo) will be very careful in distributing combination drug to make sure that everything will go smoothly for the conduct of mass drug administration for filariasis on October 13-November 15, 2008.
Dr. Patricia Grace Trabado, Iloilo Provincial Health Officer said that they will be guided with the exclusion criteria which all health workers were instructed to observe during the duration of the mass treatment for filariasis.
She said that the combination drug for mass drug administration is Diethylcabamazine citrate 50 mg, and albendazole 400 mg.
Dr. Trabado said per the exclusion criteria, the combination drug is absolutely contraindicated to pregnant women, deferred until delivery; child below 2 years old; seriously ill persons; individuals with cardiac disorder; and individuals with serious kidney disorder.
"Filariasis or Lymphatic Filariasis (LF) is transmitted to humans through bites of infected mosquitoes," said Dr.Trabado.
LF is a severely debilitating and stigmatizing disease caused by parasitic worms. These worms lodge in the lymphatic system- the network of nodes and vessels that maintain the fluid balance between the tissues and blood- which is an essential component of the body's immune system.
It will be recalled that Filariasis in Iloilo was detected from a patient of Lambunao, Iloilo. Based on the nocturnal blood survey conducted in the municipality of Lambunao, it revealed a more than 5 percent of micro-filaria rate.
The province of Iloilo was declared the 40th moderately endemic province in the country for filaria.
In connection with the filariasis elimination program, an Executive Order was also approved in October 2004, which states that the Local Government Units should lead the local implementation of filariasis mass treatment campaign, exerting special effort to encourage every family member aged 2 years and above, to take the filariasis mass treatment drugs to achieve high mass treatment coverage. (PIA) [top]